Buy Like Buffett
Watchlist

Flagship explainer

What drives AYTU BIOPHARMA, INC’s return on equity?

ROE is five filed business factors multiplied together.

DuPont return on equity factor treeReturn on equity branches into tax burden, interest burden, operating margin, asset turnover, and the equity multiplier.Return on equity−53%Tax burden100%net income ÷ pretax incomeInterest burden171%pretax ÷ operating incomeOperating margin−14%operating income ÷ revenueAsset turnover0.50×revenue ÷ average assetsEquity multiplier4.23×average assets ÷ average equityAs of 2026-06-30 · 2 SEC filing sourcesBuy Like Buffett · buylikebuffett.com
DuPont source inputs
InputValueFiscal yearSource
−$14.3MFY2026
  • 10-K · FY 2026Filing detailsAccession 0001437749-26-030908 · filed Sep 22, 2026
Income before tax−$14.2MFY2026
  • 10-K · FY 2026Filing detailsAccession 0001437749-26-030908 · filed Sep 22, 2026
Operating income−$8.3MFY2026
  • 10-K · FY 2026Filing detailsAccession 0001437749-26-030908 · filed Sep 22, 2026
$57.6MFY2026
  • 10-K · FY 2026Filing detailsAccession 0001437749-26-030908 · filed Sep 22, 2026
Ending assets$105MFY2026
  • 10-K · FY 2026Filing detailsAccession 0001437749-26-030908 · filed Sep 22, 2026
Beginning assets$124MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001437749-25-029723 · filed Sep 23, 2025
  • 10-K · FY 2025Filing detailsAccession 0001437749-26-030908 · filed Sep 22, 2026
$35.3MFY2026
  • 10-K · FY 2026Filing detailsAccession 0001437749-26-030908 · filed Sep 22, 2026
$19MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001437749-25-029723 · filed Sep 23, 2025
  • 10-K · FY 2025Filing detailsAccession 0001437749-26-030908 · filed Sep 22, 2026
Source: · event Jun 30, 2026 · retrieved Oct 16, 2026 · annual-row source set
Embed this chart

View the full AYTU BIOPHARMA, INC analysis at Buy Like Buffett